A Phase 1, Dose Escalation Study Of PF-06263507 In Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2019
Price : $35 *
At a glance
- Drugs PF 6263507 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 09 Jan 2017 Results assessing safety, pharmacokinetics, and preliminary antitumor activity of PF-06263507 in patients with advanced solid tumors published in the Investigational New Drugs.
- 17 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.